Cubist Systematic Strategies LLC Has $2.05 Million Position in Janux Therapeutics, Inc. $JANX

Key Points

• Cubist Systematic Strategies LLC increased its stake in Janux Therapeutics by 88.0% in Q1, acquiring an additional 35,511 shares to bring total holdings to 75,860 shares worth $2,048,000.
• Multiple hedge funds significantly increased their investments in Janux Therapeutics, with one, GAMMA Investing LLC, raising its stake by 1,574.0%.
• Wall Street analysts are optimistic, with a consensus rating of "Buy" and a target price averaging $85.55 for the stock.

Cubist Systematic Strategies LLC increased its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 88.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,860 shares of the company's stock after purchasing an additional 35,511 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.13% of Janux Therapeutics worth $2,048,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in Janux Therapeutics in the 4th quarter worth about $59,000. GAMMA Investing LLC increased its stake in Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after purchasing an additional 1,574 shares in the last quarter. US Bancorp DE increased its stake in Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock worth $47,000 after purchasing an additional 1,658 shares in the last quarter. FNY Investment Advisers LLC increased its stake in Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after purchasing an additional 2,425 shares in the last quarter. Finally, KBC Group NV purchased a new position in Janux Therapeutics in the 1st quarter worth about $66,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analyst Ratings Changes

JANX has been the topic of a number of analyst reports. Stifel Nicolaus reissued a "buy" rating and issued a $45.00 price target on shares of Janux Therapeutics in a research note on Wednesday. Raymond James Financial initiated coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target on the stock. Piper Sandler assumed coverage on Janux Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $42.00 price target on the stock. Guggenheim assumed coverage on Janux Therapeutics in a research note on Wednesday, September 3rd. They set a "buy" rating and a $72.00 target price on the stock. Finally, Truist Financial assumed coverage on Janux Therapeutics in a research note on Wednesday. They set a "buy" rating and a $100.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $80.92.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded down $1.07 during trading on Friday, hitting $24.05. 511,570 shares of the stock traded hands, compared to its average volume of 613,391. The stock has a market cap of $1.45 billion, a P/E ratio of -13.36 and a beta of 2.84. Janux Therapeutics, Inc. has a twelve month low of $21.97 and a twelve month high of $71.71. The company has a fifty day moving average price of $24.58 and a two-hundred day moving average price of $26.38.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.